Uroflo Capsule 0.4 mg is a prescription medicine containing Tamsulosin 0.4 mg, primarily used for the treatment of the signs and symptoms associated with Benign Prostatic Hyperplasia (BPH). BPH is a common condition in aging men characterized by enlargement of the prostate gland, which can lead to lower urinary tract symptoms such as difficulty in urination, weak urine flow, increased frequency, urgency, and nocturia. Uroflo Capsule helps improve these symptoms by relaxing the smooth muscles of the prostate and bladder neck, thereby enhancing urine flow and reducing urinary discomfort.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Uroflo Capsule 0.4 mg is indicated for the treatment of:

• Signs and symptoms of Benign Prostatic Hyperplasia (BPH)

Therapeutic Class

• BPH

• Urinary retention

• Urinary incontinence

Pharmacology

Tamsulosin is a selective antagonist of α1A-adrenoreceptors, which are predominantly located in the prostate gland, prostatic capsule, and urethra. These receptors play a key role in mediating smooth muscle contraction. By selectively and competitively binding to postsynaptic α1A-adrenoreceptors, tamsulosin causes relaxation of prostatic and urethral smooth muscle. This leads to a reduction in bladder outlet obstruction and an improvement in urinary flow without significantly affecting blood pressure.

Dosage & Administration

• The recommended dose is 0.4 mg once daily.

• The capsule should be taken approximately 30 minutes after the same meal each day.

• If there is inadequate response after 2 to 4 weeks, the dose may be increased to 0.8 mg once daily.

• If therapy is interrupted for several days, treatment should be restarted with 0.4 mg once daily, regardless of the previous dose.

• The capsule should be swallowed whole and not crushed or chewed.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• Increased plasma concentration with strong CYP3A4 inhibitors such as ketoconazole.

• Moderate CYP3A4 inhibitors (e.g., erythromycin) and strong or moderate CYP2D6 inhibitors (e.g., paroxetine, terbinafine) may increase tamsulosin exposure.

• Increased plasma concentration with cimetidine.

• Decreased plasma concentration with furosemide.

• Additive effects with other alpha-adrenergic blocking agents.

• Concomitant use with PDE5 inhibitors may result in symptomatic hypotension.

Contraindications

• History of orthostatic hypotension

• Severe hepatic impairment

Side Effects

Commonly reported side effects include dizziness and abnormal ejaculation. Less frequent adverse reactions (1–2%) include headache, asthenia, postural hypotension, palpitations, and rhinitis. Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation may occasionally occur. Hypersensitivity reactions including rash, pruritus, and urticaria have been reported. Rare cases of syncope, angioedema, and priapism have also been observed.

Pregnancy & Lactation

Uroflo Capsule 0.4 mg is not indicated for use in women, including during pregnancy and lactation.

Precautions & Warnings

• Not recommended for women and children.

• Use with caution in patients with severe renal impairment (creatinine clearance <10 mL/min).

• Patients should be advised about the risk of dizziness or hypotension, especially at the start of therapy.

Overdose Effects

Overdose may lead to hypotension. Initial management includes placing the patient in a supine position. Intravenous fluids may be administered if required. Gastric lavage, activated charcoal, or osmotic laxatives may be considered in cases of significant overdose.

Storage Conditions

• Store at 20–25°C

• Keep in a dry place away from light and moisture.

• Keep out of reach of children.

Use in Special Populations

Uroflo Capsule 0.4 mg is not indicated for pediatric use.